INDIVIOR PLC (INDV)

Company Profile

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Chesterfield Virginia, Virginia and currently employs 1,051 full-time employees. The company went IPO on 2014-12-23. The firm develops medicines to treat addiction and serious mental illnesses. The firm focuses on building a portfolio of opioid dependence treatments. The company has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The firm's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Company Info

INDIVIOR PLC

10710 Midlothian Turnpike, Suite 125, North Chesterfield

Chesterfield Virginia VIRGINIA

P: 8043791090

Employees: 1051

Website: https://www.indivior.com/en